CN109364076B - Stephania japonica extract for preventing altitude stress and gel based on same - Google Patents
Stephania japonica extract for preventing altitude stress and gel based on same Download PDFInfo
- Publication number
- CN109364076B CN109364076B CN201811505051.4A CN201811505051A CN109364076B CN 109364076 B CN109364076 B CN 109364076B CN 201811505051 A CN201811505051 A CN 201811505051A CN 109364076 B CN109364076 B CN 109364076B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- japonica extract
- stephania japonica
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a stephania japonica extract for preventing altitude stress and gel based on the stephania japonica extract, wherein the stephania japonica extract comprises the following components of stephania japonica 20-45 mg/g; 18-27 mg/g of cycleanine; and the L-tetrahydropalmatine content is 30-65 mg/g. It can effectively reduce the incidence of acute altitude stress and the incidence of acute altitude stress.
Description
Technical Field
The invention relates to the field of anti-altitude sickness drugs, and particularly relates to a stephania sinica diels extract for preventing altitude sickness and a gel based on the extract.
Background
The medical plateau refers to the area with an altitude of more than 3000 m, i.e. the altitude at which people arrive will produce different altitude reactions. The plateau region of China is very broad, the plateau region with the height of more than 3000 meters accounts for about one fourth of the total area of the national soil, is mainly distributed in Tibet, Xinjiang and Qinghai, the number of people from inland to plateau exceeds 1500 ten thousand times every year, and the plateau reaction with different degrees accounts for 60-90 percent, so that the economic development and the people health of the plateau region are restricted.
The altitude sickness, also called acute altitude sickness, is that the human body enters a plateau area with an altitude of more than 3000 meters from a plain area, and the disease is developed within hours to days, symptoms such as headache, dizziness, nausea, palpitation, chest distress, shortness of breath, hypodynamia, sleep disorder and the like appear, and serious patients can vomit, edema, somnolence, coma and even die. At present, in the market and various researches, medicines or health-care foods aiming at altitude stress are mostly based on rhodiola rosea.
Disclosure of Invention
The invention provides a stephania japonica extract for preventing altitude stress and a gel based on the stephania japonica extract to solve the technical problems.
The invention is realized by the following technical scheme:
a stephania japonica extract for preventing altitude stress comprises the following components: 20-45 mg/g cepharanthine; 18-27 mg/g of cycleanine; and the L-tetrahydropalmatine content is 30-65 mg/g.
Comprises the following components: cepharanthine 35.7 mg/g; the content of the cycleanine is 23.1 mg/g; l-tetrahydropalmatine 45.2 mg/g.
A gel for preventing altitude stress comprises the following raw materials:
37 to 85 parts by weight of solvent, 5 to 10 parts by weight of humectant, 0.03 to 0.1 part by weight of chelating agent, 0.6 to 1.3 parts by weight of thickener, 0.5 to 0.8 part by weight of pH regulator, 1.0 to 3.0 parts by weight of solubilizer, 0.004 to 0.4 part by weight of essential oil, 0.6 to 1.2 parts by weight of preservative, and 20 to 30 parts by weight of the stephania japonica extract according to claim 1 or 2.
Preferably, the cooling agent also comprises 0.6-2.0 weight parts.
Preferably, the anti-allergic agent also comprises 0.2 to 1.0 part by weight of 0.6 to 2.0 parts by weight of anti-allergic agent.
Preferably, the solvent comprises 30 to 65 parts by weight of water, 5.0 to 15.0 parts by weight of alcohol and 2.0 to 5.0 parts by weight of propylene glycol.
Preferably, the thickening agent comprises 0.5-0.8 part by weight of carbomer and 0.1-0.5 part by weight of xanthan gum.
Preferably, the essential oil comprises 0.001-0.1 weight parts of eucalyptus oil, 0.001-0.1 weight parts of nutmeg, 0.001-0.1 weight parts of ligusticum wallichii and 0.001-0.1 weight parts of sandalwood. The essential oil can be added for refreshing and tranquilizing, and rhizoma Ligustici Chuanxiong and semen Myristicae can be added for transdermal absorption to accelerate rapid absorption of effective substances of herba Stephaniae Japonicae extract in gel for treating acute hyperemesis.
Preferably, the method comprises the following raw materials: 53.58 parts by weight of a solvent, 8 parts by weight of a humectant, 0.07 part by weight of a chelating agent, 1.2 parts by weight of a thickener, 0.8 part by weight of a pH regulator, 3.0 parts by weight of a solubilizer, 0.05 part by weight of eucalyptus oil, 0.05 part by weight of nutmeg, 0.05 part by weight of Ligusticum wallichii, 0.1 part by weight of sandalwood, 0.8 part by weight of a preservative, 30 parts by weight of the above Stephania japonica extract.
Compared with the prior art, the invention has the following advantages and beneficial effects:
1. the stephania japonica extract disclosed by the invention can effectively reduce the incidence of acute altitude stress and the incidence of acute altitude stress.
2. The stephania sinica diels extract is used as a gel raw material, and the altitude stress is prevented by adopting external transdermal absorption, so that the morbidity of acute altitude stress can be effectively reduced, and the morbidity of the acute altitude stress is reduced.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to examples, and the exemplary embodiments and descriptions thereof are only used for explaining the present invention and are not used as limitations of the present invention.
Example 1
A stephania japonica extract for preventing altitude stress comprises the following components: 20-45 mg/g cepharanthine; 18-27 mg/g of cycleanine; and the L-tetrahydropalmatine content is 30-65 mg/g.
The effect is better, and the composition comprises the following components: cepharanthine 35.7 mg/g; the content of the cycleanine is 23.1 mg/g; l-tetrahydropalmatine 45.2 mg/g. The stephania japonica extract disclosed by the invention can effectively reduce the incidence of acute altitude stress and the incidence of acute altitude stress.
Example 2
A gel for preventing altitude stress comprises the following raw materials: 37-85 parts by weight of solvent, 5-10 parts by weight of humectant, 0.03-0.1 part by weight of chelating agent, 0.6-1.3 parts by weight of thickening agent, 0.5-0.8 part by weight of pH regulator, 1.0-3.0 parts by weight of solubilizer, 0.004-0.4 part by weight of essential oil, 0.6-1.2 parts by weight of preservative, and 20-30 parts by weight of stephania japonica extract as described in example 1.
Example 3
According to the preference of the public, 0.6 to 2.0 parts by weight of a cooling agent, 0.6 to 2.0 parts by weight of an anti-allergy agent and 0.02 to 0.2 part by weight of a pigment can be added into the gel on the basis of the raw materials of the above examples.
In this example, the gel was prepared from the following raw materials and their parts by weight as shown in Table 1.
TABLE 1
The gel is prepared by the following preparation method:
before presetting: the sanitary cleaning work is well done, and the equipment and the using device are well cleaned and disinfected strictly;
1. preparing a first material in advance: dissolving phase D uniformly in advance for later use; preparing a second preparation: mixing and dispersing the phase E uniformly in advance for later use;
2. accurately weighing phase A, putting the phase A into a clean main pot, homogenizing for 5-10 minutes, adding phase B, homogenizing for 3-5 minutes, stirring and heating to 85-88 ℃, after homogenizing for 5-10 minutes, keeping the temperature for 20 minutes in vacuum, and cooling after no fine particles or obvious bubbles exist;
3. cooling to 60 ℃, adding the phase C, stirring uniformly, and continuously cooling;
4. and (3) sequentially adding the prepared D phase, E phase, F phase and G phase at 42 ℃, uniformly stirring, adding a proper amount of H phase, performing inching homogenization for about 20 seconds, sampling and detecting, and discharging and sealing after the plate is qualified.
The medicine is applied to the skin of temples, behind ears, eyebrows, neck, umbilicus and the like in a proper amount 2 hours before and after entering a high-altitude area, and is repeatedly used every 2-4 hours. According to the clinical symptoms self-test questionnaire of altitude stress formulated according to the national military standard GJB 1098-91 of the people's republic of China and the diagnosis and treatment principles of acute altitude stress, the results of human body tests show that by using the gel provided by the invention, the graduation score of the symptoms of acute altitude stress can be obviously reduced compared with a control group, and the incidence of acute altitude stress can be effectively reduced.
Example 4
In this example, the phases and their contents are given in table 2 below:
the gel prepared according to the above ratio, the implementation and test data of the human body test are shown in the following table 2. The test subjects are 162 male Han nationality new soldiers, are healthy, are 18-22 years old, enter high-altitude areas for the first time, and are randomly and averagely divided into an experimental group and a control group. The gel is applied to the skin of temple, behind ear, eyebrow, neck, umbilicus and the like in a proper amount 2 hours before and after entering the high-altitude area, and is repeatedly used every 2-4 hours later. The control group did not use any anti-hyperreflexia agent, and was not treated differently from the experimental group except that it was treated with gel.
The experimental group was continuously used 2 hours before entering high altitude area, i.e. altitude 3680 m, and 5 days after entering, and scored using "altitude response clinical symptoms self-test questionnaire" on days 1, 2, 3, 4, and 5, with the results as follows:
table 3: AMS symptom score and incidence comparison between experimental and control groups (n = 81)
Acute altitude diseases are pathological reactions generated after a human body is exposed to a hypoxic environment for a short time. After entering the high-sea area, the number of people with acute altitude diseases is parabolic with the increase of days in the control group, and the number of people with high adverse reaction is the most on the 3 rd day. The number of people who have acute altitude sickness is also in a parabola form in the experimental group coated with the gel, but the incidence rate of acute altitude sickness can be effectively reduced, and particularly, the comparison effect is better after the number of days of use is increased.
The above-mentioned embodiments are intended to illustrate the objects, technical solutions and advantages of the present invention in further detail, and it should be understood that the above-mentioned embodiments are merely exemplary embodiments of the present invention, and are not intended to limit the scope of the present invention, and any modifications, equivalent substitutions, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (9)
1. The application of the stephania japonica extract in preparing the medicine for preventing the altitude stress is characterized in that the stephania japonica extract comprises 20-45 mg/g of stephanine, 18-27 mg/g of cycleanine and 30-65 mg/g of L-tetrahydropalmatine.
2. The use of stephania japonica extract according to claim 1 in the preparation of a medicament for preventing altitude stress, wherein the stephania japonica extract comprises: 35.7mg/g of cepharanthine, 23.1mg/g of cycleanine and 45.2mg/g of L-tetrahydropalmatine.
3. The application of the stephania japonica extract in preparing the gel for preventing the altitude stress is characterized in that the gel comprises the following raw materials:
37 to 85 parts by weight of solvent, 5 to 10 parts by weight of humectant, 0.03 to 0.1 part by weight of chelating agent, 0.6 to 1.3 parts by weight of thickener, 0.5 to 0.8 part by weight of pH regulator, 1.0 to 3.0 parts by weight of solubilizer, 0.6 to 1.2 parts by weight of preservative, 0.004 to 0.4 part by weight of essential oil, 20 to 30 parts by weight of the stephania japonica extract as described in claim 1 or 2.
4. The application of stephania japonica extract in preparing gel for preventing altitude stress according to claim 3, further comprising 0.6-2.0 parts by weight of a cooling agent.
5. The application of stephania japonica extract in preparing gel for preventing altitude stress according to claim 3, further comprising 0.2-1.0 part by weight of an anti-allergic agent.
6. The use of stephania japonica extract in preparing a gel for preventing altitude stress according to claim 3, wherein the solvent comprises 30 to 65 parts by weight of water, 5.0 to 15.0 parts by weight of alcohol, and 2.0 to 5.0 parts by weight of propylene glycol.
7. The application of stephania japonica extract in preparing a gel for preventing altitude stress according to claim 3, wherein the thickener comprises 0.5-0.8 parts by weight of carbomer and 0.1-0.5 parts by weight of xanthan gum.
8. The use of the stephania japonica extract according to claim 3, wherein the essential oil comprises 0.001 to 0.1 parts by weight of eucalyptus oil, 0.001 to 0.1 parts by weight of nutmeg, 0.001 to 0.1 parts by weight of ligusticum wallichii, and 0.001 to 0.1 parts by weight of sandalwood.
9. The application of stephania japonica extract in preparing gel for preventing altitude stress according to claim 8, wherein the gel comprises the following raw materials: 53.58 parts by weight of a solvent, 8 parts by weight of a humectant, 0.07 parts by weight of a chelating agent, 1.2 parts by weight of a thickener, 0.8 parts by weight of a PH adjuster, 3.0 parts by weight of a solubilizer, 0.05 parts by weight of eucalyptus oil, 0.05 parts by weight of nutmeg, 0.05 parts by weight of ligusticum wallichii, 0.1 parts by weight of sandalwood, 0.8 parts by weight of a preservative, 30 parts by weight of the stephania japonica extract according to claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811505051.4A CN109364076B (en) | 2018-12-10 | 2018-12-10 | Stephania japonica extract for preventing altitude stress and gel based on same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811505051.4A CN109364076B (en) | 2018-12-10 | 2018-12-10 | Stephania japonica extract for preventing altitude stress and gel based on same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109364076A CN109364076A (en) | 2019-02-22 |
| CN109364076B true CN109364076B (en) | 2021-02-26 |
Family
ID=65373079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811505051.4A Active CN109364076B (en) | 2018-12-10 | 2018-12-10 | Stephania japonica extract for preventing altitude stress and gel based on same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109364076B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113956936A (en) * | 2021-08-27 | 2022-01-21 | 西藏达热瓦青稞酒业股份有限公司 | Preparation method of canned highland barley wine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103330728A (en) * | 2013-07-17 | 2013-10-02 | 贾正平 | Preparation method and application of saussurea involucrate flavonoid capsule |
| CN103877084B (en) * | 2014-04-14 | 2015-09-23 | 崔新明 | A kind of external used medicine for the treatment of Perianal ulceration |
-
2018
- 2018-12-10 CN CN201811505051.4A patent/CN109364076B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109364076A (en) | 2019-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19953829C2 (en) | Nasal spray (drops) for the treatment of fever, cold and its manufacture | |
| CN104306651A (en) | Tibetan medicine composition with whitening and freckle removing function and application and preparation method of Tibetan medicine composition | |
| CN109364076B (en) | Stephania japonica extract for preventing altitude stress and gel based on same | |
| CN105232976A (en) | Composition for preventing and/or treating sub-health | |
| CN109431973B (en) | Preparation method of gel for preventing altitude stress | |
| Modaresi et al. | The effects of aloe vera extract on reproductive parameters in mice | |
| CN103877376B (en) | A kind of pharmaceutical preparation treating depression | |
| CN102631623A (en) | Traditional Chinese medicine composite for treating thyroid associated ophthalmopathy and preparation method thereof | |
| CN105213972A (en) | A kind of pharmaceutical preparation of promoting blood circulation to remove obstruction in the collateral and application thereof | |
| CN105194352B (en) | A kind of Chinese medicine composition and preparation method thereof improving learning and memory | |
| CN105687037B (en) | A kind of Traditional Chinese medicine acne treatment mask and preparation method thereof | |
| CN110251624B (en) | Preparation method of acne eliminating gel | |
| CN104069171A (en) | Antidepressant medicine composition as well as preparation method and application thereof | |
| CN104740579B (en) | Premenstrual peace piece and its preparation technology | |
| CN110934908A (en) | Compound nutritional health product capable of increasing body temperature to prevent diseases | |
| CN107375700A (en) | A kind of herbal composition preparation with prevention and treatment male infertility infertility | |
| CN107320662A (en) | Traditional Chinese medicine composition for treating nasopharyngeal carcinoma and cooperating with nasopharyngeal carcinoma chemoradiotherapy | |
| CN108404082B (en) | Compound traditional Chinese medicine preparation with effects of promoting blood circulation and relieving pain and preparation method thereof | |
| CN107126508A (en) | A kind of pharmaceutical composition for preventing and treating senile dementia and preparation method thereof | |
| CN106420934A (en) | Traditional Chinese medicine composition with effect of assisting blood sugar lowering and preparation method and product thereof | |
| CN118356470A (en) | Traditional Chinese medicine composition for treating coronary heart disease and angina pectoris with syndrome of turbid phlegm and blood stasis and preparation method thereof | |
| CN117815337A (en) | Traditional Chinese medicine composition for treating angioneurotic headache | |
| CN111068026A (en) | Wind-heat type common cold conditioning bath powder and preparation method thereof | |
| CN103705868A (en) | Pharmaceutical composition for treating hyperthyroidism and application thereof | |
| CN104524245A (en) | Traditional Chinese medicine composition for treating attention deficit hyperactivity disorder and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |